Trial NCT04456595
Publication Palacios R, SSRN, 2021
Primary outcome on the report: The primary endpoint was the efficacy of CoronaVac against confirmed symptomatic COVID-19 with onset at least 14 days after the second injection in the per protocol population. The primary safety endpoint was incidence of adverse reactions within 7 days after injection.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.